Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2005 Apr;60(4):335–342. doi: 10.1136/thx.2004.028712

Assessment of progression of COPD: report of a workshop held in Leuven, 11–12 March 2004

M Decramer 1, R Gosselink 1, M Rutten-Van 1, J Buffels 1, O Van Schayck 1, P Gevenois 1, R Pellegrino 1, E Derom 1, W De Backer 1
PMCID: PMC1747360  PMID: 15790991

Abstract

Recently performed long term trials have enhanced the insight into the assessment of progression of COPD. The present review focuses on the initial assessment of COPD in general practice and the assessment of disease progression. Several variables may be used to assess this progression, all of which are associated with significant methodological problems. Finding the appropriate mix of outcome measures to capture all aspects of disease progression is a significant challenge.

Full Text

The Full Text of this article is available as a PDF (104.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson F., Borg S., Jansson S. A., Jonsson A. C., Ericsson A., Prütz C., Rönmark E., Lundbäck B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002 Sep;96(9):700–708. doi: 10.1053/rmed.2002.1334. [DOI] [PubMed] [Google Scholar]
  2. Anthonisen N. R., Connett J. E., Kiley J. P., Altose M. D., Bailey W. C., Buist A. S., Conway W. A., Jr, Enright P. L., Kanner R. E., O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497–1505. [PubMed] [Google Scholar]
  3. Antonelli-Incalzi R., Imperiale C., Bellia V., Catalano F., Scichilone N., Pistelli R., Rengo F., SaRA Investigators Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J. 2003 Sep;22(3):444–449. doi: 10.1183/09031936.03.00101203. [DOI] [PubMed] [Google Scholar]
  4. Bailey P. H. Death stories: acute exacerbations of chronic obstructive pulmonary disease. Qual Health Res. 2001 May;11(3):322–338. doi: 10.1177/104973201129119136. [DOI] [PubMed] [Google Scholar]
  5. Bestall J. C., Paul E. A., Garrod R., Garnham R., Jones R. W., Wedzicha A. J. Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respir Med. 2003 Feb;97(2):173–180. doi: 10.1053/rmed.2003.1397. [DOI] [PubMed] [Google Scholar]
  6. Briggs A. H. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000 May;17(5):479–500. doi: 10.2165/00019053-200017050-00006. [DOI] [PubMed] [Google Scholar]
  7. Buffels Johan, Degryse Jan, Heyrman Jan, Decramer Marc, DIDASCO Study Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004 Apr;125(4):1394–1399. doi: 10.1378/chest.125.4.1394. [DOI] [PubMed] [Google Scholar]
  8. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burrows B., Earle R. H. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med. 1969 Feb 20;280(8):397–404. doi: 10.1056/NEJM196902202800801. [DOI] [PubMed] [Google Scholar]
  10. Calverley Peter, Pauwels Romain, Vestbo Jørgen, Jones Paul, Pride Neil, Gulsvik Amund, Anderson Julie, Maden Claire, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2. [DOI] [PubMed] [Google Scholar]
  11. Carver C. S., Scheier M. F. Scaling back goals and recalibration of the affect system are processes in normal adaptive self-regulation: understanding 'response shift' phenomena. Soc Sci Med. 2000 Jun;50(12):1715–1722. doi: 10.1016/s0277-9536(99)00412-8. [DOI] [PubMed] [Google Scholar]
  12. Casaburi R., Mahler D. A., Jones P. W., Wanner A., San Pedro G., ZuWallack R. L., Menjoge S. S., Serby C. W., Witek T., Jr A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002 Feb;19(2):217–224. doi: 10.1183/09031936.02.00269802. [DOI] [PubMed] [Google Scholar]
  13. Decramer M., Dekhuijzen P. N., Troosters T., van Herwaarden C., Rutten-van Mölken M., van Schayck C. P., Olivieri D., Lankhorst I., Ardia A. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. Eur Respir J. 2001 Mar;17(3):329–336. doi: 10.1183/09031936.01.17303290. [DOI] [PubMed] [Google Scholar]
  14. Dewan N. A., Rafique S., Kanwar B., Satpathy H., Ryschon K., Tillotson G. S., Niederman M. S. Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest. 2000 Mar;117(3):662–671. doi: 10.1378/chest.117.3.662. [DOI] [PubMed] [Google Scholar]
  15. Dirksen A., Dijkman J. H., Madsen F., Stoel B., Hutchison D. C., Ulrik C. S., Skovgaard L. T., Kok-Jensen A., Rudolphus A., Seersholm N. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 1):1468–1472. doi: 10.1164/ajrccm.160.5.9901055. [DOI] [PubMed] [Google Scholar]
  16. Dirksen A., Holstein-Rathlou N. H., Madsen F., Skovgaard L. T., Ulrik C. S., Heckscher T., Kok-Jensen A. Long-range correlations of serial FEV1 measurements in emphysematous patients and normal subjects. J Appl Physiol (1985) 1998 Jul;85(1):259–265. doi: 10.1152/jappl.1998.85.1.259. [DOI] [PubMed] [Google Scholar]
  17. Domingo-Salvany Antònia, Lamarca Rosa, Ferrer Montserrat, Garcia-Aymerich Judith, Alonso Jordi, Félez Miquel, Khalaf Ahmad, Marrades Ramon M., Monsó Eduard, Serra-Batlles Joan. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 1;166(5):680–685. doi: 10.1164/rccm.2112043. [DOI] [PubMed] [Google Scholar]
  18. Eaton T., Withy S., Garrett J. E., Mercer J., Whitlock R. M., Rea H. H. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest. 1999 Aug;116(2):416–423. doi: 10.1378/chest.116.2.416. [DOI] [PubMed] [Google Scholar]
  19. Fan Vincent S., Curtis J. Randall, Tu Shin-Ping, McDonell Mary B., Fihn Stephan D., Ambulatory Care Quality Improvement Project Investigators Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest. 2002 Aug;122(2):429–436. doi: 10.1378/chest.122.2.429. [DOI] [PubMed] [Google Scholar]
  20. Ferrer M., Alonso J., Prieto L., Plaza V., Monsó E., Marrades R., Aguar M. C., Khalaf A., Antó J. M. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J. 1996 Jun;9(6):1160–1166. doi: 10.1183/09031936.96.09061160. [DOI] [PubMed] [Google Scholar]
  21. Goldstein R. S., Gort E. H., Guyatt G. H., Feeny D. Economic analysis of respiratory rehabilitation. Chest. 1997 Aug;112(2):370–379. doi: 10.1378/chest.112.2.370. [DOI] [PubMed] [Google Scholar]
  22. Grasso M. E., Weller W. E., Shaffer T. J., Diette G. B., Anderson G. F. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Jul;158(1):133–138. doi: 10.1164/ajrccm.158.1.9710041. [DOI] [PubMed] [Google Scholar]
  23. Güell R., Casan P., Belda J., Sangenis M., Morante F., Guyatt G. H., Sanchis J. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest. 2000 Apr;117(4):976–983. doi: 10.1378/chest.117.4.976. [DOI] [PubMed] [Google Scholar]
  24. Hajiro T., Nishimura K., Tsukino M., Ikeda A., Koyama H., Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Oct;158(4):1185–1189. doi: 10.1164/ajrccm.158.4.9802091. [DOI] [PubMed] [Google Scholar]
  25. Hilleman D. E., Dewan N., Malesker M., Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000 Nov;118(5):1278–1285. doi: 10.1378/chest.118.5.1278. [DOI] [PubMed] [Google Scholar]
  26. Jackson Hannah, Hubbard Richard. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ. 2003 Sep 20;327(7416):653–654. doi: 10.1136/bmj.327.7416.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jansson Sven-Arne, Andersson Fredrik, Borg Sixten, Ericsson Asa, Jönsson Elsy, Lundbäck Bo. Costs of COPD in Sweden according to disease severity. Chest. 2002 Dec;122(6):1994–2002. doi: 10.1378/chest.122.6.1994. [DOI] [PubMed] [Google Scholar]
  28. Jones P. W., Bosh T. K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997 Apr;155(4):1283–1289. doi: 10.1164/ajrccm.155.4.9105068. [DOI] [PubMed] [Google Scholar]
  29. Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327. doi: 10.1164/ajrccm/145.6.1321. [DOI] [PubMed] [Google Scholar]
  30. Jones P. W., Wilson K., Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med. 2003 Jan;97(1):20–26. doi: 10.1053/rmed.2002.1425. [DOI] [PubMed] [Google Scholar]
  31. Lundbäck B., Lindberg A., Lindström M., Rönmark E., Jonsson A. C., Jönsson E., Larsson L. G., Andersson S., Sandström T., Larsson K. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003 Feb;97(2):115–122. doi: 10.1053/rmed.2003.1446. [DOI] [PubMed] [Google Scholar]
  32. Macklem P. T., Thurlbeck W. M., Fraser R. G. Chronic obstructive disease of small airways. Ann Intern Med. 1971 Feb;74(2):167–177. doi: 10.7326/0003-4819-74-2-167. [DOI] [PubMed] [Google Scholar]
  33. Mahon J., Laupacis A., Donner A., Wood T. Randomised study of n of 1 trials versus standard practice. BMJ. 1996 Apr 27;312(7038):1069–1074. doi: 10.1136/bmj.312.7038.1069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Marquis Karine, Debigaré Richard, Lacasse Yves, LeBlanc Pierre, Jobin Jean, Carrier Guy, Maltais François. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002 Sep 15;166(6):809–813. doi: 10.1164/rccm.2107031. [DOI] [PubMed] [Google Scholar]
  35. Miravitlles Marc, Murio Cristina, Guerrero Tina, Gisbert Ramon. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003 Mar;123(3):784–791. doi: 10.1378/chest.123.3.784. [DOI] [PubMed] [Google Scholar]
  36. Miravitlles Marc, Murio Cristina, Guerrero Tina, Gisbert Ramon, DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002 May;121(5):1449–1455. doi: 10.1378/chest.121.5.1449. [DOI] [PubMed] [Google Scholar]
  37. Newton Marcus F., O'Donnell Denis E., Forkert Lutz. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest. 2002 Apr;121(4):1042–1050. doi: 10.1378/chest.121.4.1042. [DOI] [PubMed] [Google Scholar]
  38. O'Donnell D. E., Lam M., Webb K. A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1557–1565. doi: 10.1164/ajrccm.158.5.9804004. [DOI] [PubMed] [Google Scholar]
  39. Oostenbrink J. B., Rutten-van Mölken M. P. M. H., Al M. J., Van Noord J. A., Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004 Feb;23(2):241–249. doi: 10.1183/09031936.03.00083703. [DOI] [PubMed] [Google Scholar]
  40. Oostenbrink Jan B., Al Maiwenn J., Rutten-van Mölken Maureen P. M. H. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics. 2003;21(15):1103–1112. doi: 10.2165/00019053-200321150-00004. [DOI] [PubMed] [Google Scholar]
  41. Oostenbrink Jan B., Rutten-van Mölken Maureen P. M. H. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med. 2004 Sep;98(9):883–891. doi: 10.1016/j.rmed.2004.02.013. [DOI] [PubMed] [Google Scholar]
  42. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  43. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  44. Pechevis M., Fagnani F., Brin S., De Zelicourt M., Morales M. Infections respiratoires récidivantes du sujet atteint de bronchite chronique obstructive: prise en charge médicale et coûts. Rev Mal Respir. 1996 Oct;13(5):507–512. [PubMed] [Google Scholar]
  45. Pellegrino R., Rodarte J. R., Brusasco V. Assessing the reversibility of airway obstruction. Chest. 1998 Dec;114(6):1607–1612. doi: 10.1378/chest.114.6.1607. [DOI] [PubMed] [Google Scholar]
  46. Pinto-Plata V. M., Cote C., Cabral H., Taylor J., Celli B. R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004 Jan;23(1):28–33. doi: 10.1183/09031936.03.00034603. [DOI] [PubMed] [Google Scholar]
  47. Quanjer P. H., Tammeling G. J., Cotes J. E., Pedersen O. F., Peslin R., Yernault J. C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993 Mar;16:5–40. [PubMed] [Google Scholar]
  48. Rennard S., Decramer M., Calverley P. M. A., Pride N. B., Soriano J. B., Vermeire P. A., Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002 Oct;20(4):799–805. doi: 10.1183/09031936.02.03242002. [DOI] [PubMed] [Google Scholar]
  49. Ries Andrew L., Kaplan Robert M., Myers Roseann, Prewitt Lela M. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med. 2002 Dec 27;167(6):880–888. doi: 10.1164/rccm.200204-318OC. [DOI] [PubMed] [Google Scholar]
  50. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S–401S. doi: 10.1378/chest.117.5_suppl_2.398s. [DOI] [PubMed] [Google Scholar]
  51. Ruchlin H. S., Dasbach E. J. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics. 2001;19(6):623–642. doi: 10.2165/00019053-200119060-00002. [DOI] [PubMed] [Google Scholar]
  52. Rutten-van Mölken M. P., Postma M. J., Joore M. A., Van Genugten M. L., Leidl R., Jager J. C. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med. 1999 Nov;93(11):779–787. doi: 10.1016/s0954-6111(99)90262-7. [DOI] [PubMed] [Google Scholar]
  53. Rutten-van Mölken M., Roos B., Van Noord J. A. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax. 1999 Nov;54(11):995–1003. doi: 10.1136/thx.54.11.995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rychlik R., Pfeil T., Daniel D., Pfeil B., Mast O., Thate-Waschke I., Lorenz J. Zur sozioökonomischen Relevanz akuter Exazerbationen der chronischen Bronchitis in der Bundesrepublik Deutschland. Eine prospektive Krankheitskostenstudie. Dtsch Med Wochenschr. 2001 Mar 30;126(13):353–359. doi: 10.1055/s-2001-12393. [DOI] [PubMed] [Google Scholar]
  55. Schermer T. R., Jacobs J. E., Chavannes N. H., Hartman J., Folgering H. T., Bottema B. J., van Weel C. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax. 2003 Oct;58(10):861–866. doi: 10.1136/thorax.58.10.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Schünemann Holger J., Griffith Lauren, Jaeschke Roman, Goldstein Roger, Stubbing David, Austin Peggy, Guyatt Gordon H. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest. 2003 Oct;124(4):1421–1429. doi: 10.1378/chest.124.4.1421. [DOI] [PubMed] [Google Scholar]
  57. Seemungal T. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Wedzicha J. A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608–1613. doi: 10.1164/ajrccm.161.5.9908022. [DOI] [PubMed] [Google Scholar]
  58. Seemungal T. A., Donaldson G. C., Paul E. A., Bestall J. C., Jeffries D. J., Wedzicha J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  59. Siafakas N. M., Vermeire P., Pride N. B., Paoletti P., Gibson J., Howard P., Yernault J. C., Decramer M., Higenbottam T., Postma D. S. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995 Aug;8(8):1398–1420. doi: 10.1183/09031936.95.08081398. [DOI] [PubMed] [Google Scholar]
  60. Spencer S., Calverley P. M. A., Burge P. S., Jones P. W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698–702. doi: 10.1183/09031936.04.00121404. [DOI] [PubMed] [Google Scholar]
  61. Spencer S., Jones P. W., GLOBE Study Group Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003 Jul;58(7):589–593. doi: 10.1136/thorax.58.7.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Strassels S. A., Smith D. H., Sullivan S. D., Mahajan P. S. The costs of treating COPD in the United States. Chest. 2001 Feb;119(2):344–352. doi: 10.1378/chest.119.2.344. [DOI] [PubMed] [Google Scholar]
  63. Sullivan S. D., Ramsey S. D., Lee T. A. The economic burden of COPD. Chest. 2000 Feb;117(2 Suppl):5S–9S. doi: 10.1378/chest.117.2_suppl.5s. [DOI] [PubMed] [Google Scholar]
  64. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 Jan;21(1):74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  65. Troosters T., Gosselink R., Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000 Aug 15;109(3):207–212. doi: 10.1016/s0002-9343(00)00472-1. [DOI] [PubMed] [Google Scholar]
  66. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  67. Vincken W., van Noord J. A., Greefhorst A. P. M., Bantje Th A., Kesten S., Korducki L., Cornelissen P. J. G., Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002 Feb;19(2):209–216. doi: 10.1183/09031936.02.00238702. [DOI] [PubMed] [Google Scholar]
  68. Wouters E. F. M. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med. 2003 Mar;97 (Suppl 100):S3–14. doi: 10.1016/s0954-6111(03)80020-3. [DOI] [PubMed] [Google Scholar]
  69. Zieliñski J., Bednarek M., Know the Age of Your Lung Study Group Early detection of COPD in a high-risk population using spirometric screening. Chest. 2001 Mar;119(3):731–736. doi: 10.1378/chest.119.3.731. [DOI] [PubMed] [Google Scholar]
  70. de Miguel Díez J., Izquierdo Alonso J. L., Molina París J., Rodríguez González-Moro J. M., de Lucas Ramos P., Gaspar Alonso-Vega G. Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos. Arch Bronconeumol. 2003 May;39(5):203–208. doi: 10.1016/s0300-2896(03)75362-9. [DOI] [PubMed] [Google Scholar]
  71. van Stel Henk F., Maillé A. Rianne, Colland Vivian T., Everaerd Walter. Interpretation of change and longitudinal validity of the quality of life for respiratory illness questionnaire (QoLRIQ) in inpatient pulmonary rehabilitation. Qual Life Res. 2003 Mar;12(2):133–145. doi: 10.1023/a:1022213223673. [DOI] [PubMed] [Google Scholar]
  72. van den Boom G., Rutten-van Mölken M. P., Tirimanna P. R., van Schayck C. P., Folgering H., van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J. 1998 Jan;11(1):67–72. doi: 10.1183/09031936.98.11010067. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES